GU Cancers 2019 | KEYNOTE-426 rationale and results: pembro plus axitinib vs. sunitinib in mRCC

Thomas Powles

Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, talks about the rationale and results of the Phase III KEYNOTE-426 study (NCT02853331), investigating the combination of pembrolizumab plus axitinib vs. sunitinib monotherapy in metastatic renal cell carcinoma (mRCC). Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. Powles highlights that the combined use of pembrolizumab and axitinib demonstrated a clinically promising survival advantage, progression-free survival, and response rate in patients.

Share this video